WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 5, 1501-1514. Review Article ISSN 2277–7105

# FROM CLINICS TO COMPLIANCE: THE ROLE OF AI IN ADVANCING MENORRHAGIA TREATMENT AND REGULATORY OVERSIGHT

**Acharya Vaishnavi Kamlesh*[1], Syed Shoaib Ali[2]**

[1]Second Year M. Pharmacy, Department of Regulatory Affairs, Dr. Vedprakash Patil Pharmacy College, Georai Tanda, Dist- Chhatrapati Sambhajinagar, India – 431105.

[2]Assistant Professor, Dr. Vedprakash Patil Pharmacy College, Georai Tanda, Dist- Chhatrapati Sambhajinagar, India – 431105.

Article Received on 05 Feb. 2026,
Article Revised on 25 Feb. 2026,
Article Published on 01 March 2026,

https://doi.org/10.5281/zenodo.18884322

***Corresponding Author**

**Acharya Vaishnavi Kamlesh**

Second Year M. Pharmacy, Department of Regulatory Affairs, Dr. Vedprakash Patil Pharmacy College, Georai Tanda, Dist- Chhatrapati Sambhajinagar, India – 431105.

**How to cite this Article:** Acharya Vaishnavi Kamlesh*[1], Syed Shoaib Ali[2]. (2026). From Clinics To Compliance: The Role Of Ai In Advancing Menorrhagia Treatment And Regulatory Oversight World Journal of Pharmaceutical Research, 15(5), 1501–1514.


## ABSTRACT

Menorrhagia, or Heavy Menstrual Bleeding (HMB), is a common gynecological disorder that significantly affects women's health and quality of life. Conventional diagnostic and treatment approaches often rely on subjective assessment and standardized therapies, leading to delayed diagnosis and inconsistent clinical outcomes. Artificial Intelligence (AI) has emerged as a promising tool in healthcare, enabling improved diagnostic accuracy, predictive analytics, personalized treatment planning, and continuous monitoring through digital platforms. AI-based systems can analyze medical imaging, menstrual health data, and clinical records to support timely and evidence-based clinical decisions. However, the adoption of AI in healthcare introduces important regulatory challenges, including software validation, data privacy, cybersecurity, algorithm transparency, and lifecycle management under Software as a Medical Device (SaMD) frameworks. Regulatory authorities such as FDA, EMA, and CDSCO are developing guidance to ensure safe and effective integration of AI technologies. This review highlights the role of AI in advancing menorrhagia treatment while emphasizing the importance of strong regulatory oversight for ethical and compliant implementation. **Conclusion:** Artificial Intelligence offers promising advancements in the diagnosis and management of menorrhagia. However, effective

regulatory oversight is essential to ensure safety, transparency, and ethical implementation. A balanced integration of innovation and compliance will support the responsible adoption of AI in women's healthcare.

**KEYWORDS:** Artificial Intelligence; Menorrhagia; Heavy Menstrual Bleeding; Regulatory Oversight; Software as a Medical Device (SaMD); Digital Health; Healthcare Compliance; Medical Device Regulation.

## INTRODUCTION

Menorrhagia, or Heavy Menstrual Bleeding (HMB), is among the most common gynecological disorders affecting reproductive-age women. Clinically, it is defined as menstrual blood loss exceeding 80 mL per cycle or bleeding lasting more than 7 days. Globally, up to one-third of women suffer from HMB, yet a large majority remain undiagnosed, attributing symptoms to normal menstruation or hesitating to seek medical care. Prolonged menorrhagia leads to iron deficiency anemia, hospitalization, chronic fatigue, psychological distress, social withdrawal, and reduced productivity.

Traditional diagnosis relies heavily on subjective reporting, pelvic imaging, blood tests, and hysteroscopic evaluation. Treatment may include NSAIDs, hormonal therapies, Tranexamic acid, LNG-IUS, endometrial ablation, or hysterectomy. However, outcomes vary due to time-consuming clinical evaluation, varied etiologies, and limited personalization of therapy.

Artificial Intelligence has recently emerged as a revolutionary tool in women's healthcare. AI models can.

- Analyze medical images such as ultrasound, MRI, and Hysteroscopy for early lesion detection
- Predict disease progression and treatment outcomes
- Assist doctors in choosing the most personalized and effective clinical approach
- Monitor menstrual patterns via digital platforms and wearables

  Menstrual tracking apps integrated with machine learning can automatically identify symptoms of abnormal uterine bleeding. AI-driven image interpretation can differentiate between structural and non-structural causes based on FIGO PALM-COEIN classification.

  However, AI in healthcare introduces regulatory concerns such as:

- Software validation and real-world performance monitoring

- Data privacy and security
- "Black box" transparency issues
- Cybersecurity threats
- Bias in machine learning due to poor data diversity
- Classification of AI as a medical device

Hence, a regulatory-scientific convergence is essential to ensure that AI-based decision-making systems for menorrhagia are clinically safe, ethically compliant, and globally standardized.

**Limitations of Study**

1. Literature-based secondary data

   This study relies purely on available scientific literature, regulatory guidance documents, and digital health reports. No primary clinical trial data or patient-specific AI model testing is included.
2. Rapidly evolving AI technologies

   Artificial Intelligence in healthcare is continuously advancing, and regulatory policies are frequently updated. Newer developments may emerge after the completion of this study.
3. Limited regional implementation evidence

   There is insufficient published data on the application of AI for menorrhagia management in rural or resource-limited Indian settings, which may influence the generalizability of outcomes.
4. Algorithmic transparency issues

   Many AI studies do not provide technical details regarding data training sources, algorithm design, or bias prevention, restricting full regulatory evaluation.
5. Variability in clinical definitions and diagnosis
6. Menorrhagia diagnosis often depends on subjective symptom reporting, leading to inconsistent clinical endpoints in the reviewed studies.
7. Data privacy and cybersecurity research gaps

   Regulatory literature on menstrual health data protection in India remains limited compared to Western countries, making ethical assessment region-specific.

**Review of Literature**

1. Menorrhagia is a common gynecological condition with significant clinical and socioeconomic impact, often leading to anemia, reduced productivity, and impaired

quality of life. Conventional diagnostic and treatment approaches largely depend on subjective clinical evaluation and invasive procedures, which may result in delayed diagnosis and inconsistent outcomes.[1][2] Recent studies highlight the need for innovative, technology-driven solutions to improve accuracy and continuity of care.

2. Artificial Intelligence (AI) has gained increasing attention in healthcare due to its ability to analyze large and complex datasets and support clinical decision-making. Several authors have reported that AI-based systems can identify patterns in patient data that are not easily detectable through traditional methods, thereby offering potential benefits in the management of menstrual disorders such as menorrhagia.[3][4]

3. Machine learning algorithms have been applied to menstrual health data obtained from mobile health applications, wearable devices, and electronic health records. These studies demonstrate that AI models can effectively monitor bleeding patterns, predict symptom severity, and assist in early identification of abnormal menstrual bleeding, improving clinical consistency and patient follow-up.[5][6]

4. AI-assisted diagnostic tools, including image analysis and decision-support systems, have shown promise in enhancing the detection of underlying gynecological conditions associated with menorrhagia. Literature suggests that these technologies reduce inter-observer variability and support clinicians in making more accurate and timely diagnostic decisions.[7][8]

5. In the therapeutic domain, AI-driven predictive models have been explored to support individualized treatment planning. Researchers report that AI can integrate clinical, laboratory, and historical treatment data to recommend optimized management strategies, contributing to a more personalized approach to menorrhagia care.[9][10]

6. Alongside clinical advancements, the growing use of AI has raised important regulatory considerations. Regulatory science literature emphasizes that AI-enabled medical technologies require robust oversight to ensure safety, effectiveness, and reliability throughout their lifecycle.[11][12]

7. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organization (CDSCO) have introduced guidance documents addressing artificial intelligence and machine

learning-based medical devices. These frameworks focus on validation, transparency, change management, and post-market surveillance of AI systems.[13][14][15]

8. Studies also highlight the role of AI in supporting regulatory compliance through automated documentation, data management, and risk assessment tools. AI-enabled regulatory systems have been reported to improve submission quality, reduce review timelines, and enhance communication between developers and regulatory authorities.[16][17]

9. Ethical and legal challenges remain a major concern in the adoption of AI in healthcare. Several authors point out issues related to algorithmic bias, explainability, patient data privacy, and accountability, which must be addressed to ensure trustworthy and acceptable AI applications in clinical practice.[18][19]

10. Recent reviews emphasize the absence of harmonized global regulatory standards for AI-enabled healthcare technologies. Variations in regulatory expectations across regions pose challenges for developers seeking multi-country approvals, particularly for digital health solutions addressing conditions such as menorrhagia.[20][21]

11. Overall, existing literature supports the potential of AI to improve both clinical management and regulatory oversight in menorrhagia treatment. However, researchers consistently stress the importance of integrating technological innovation with strong regulatory frameworks, ethical governance, and clinical validation.[22][23]

12. The present study builds upon this existing body of knowledge to critically evaluate the role of artificial intelligence from clinical application to regulatory compliance, with the aim of identifying gaps, challenges, and future opportunities in the safe and effective adoption of AI for menorrhagia management.[24][25]

**Need of the study, Rationale and Justification**

**Need of the Study**

Menorrhagia is a prevalent yet frequently underdiagnosed clinical condition that significantly affects the quality of life, productivity, and overall health outcomes of women. Conventional diagnostic and treatment approaches rely heavily on subjective symptom reporting, manual interpretation of imaging data, and standardized treatment protocols, which often fail to address individual variability and delay timely intervention.

The emergence of Artificial Intelligence (AI) offers promising solutions to overcome these limitations by enabling early detection, accurate diagnosis, personalized treatment planning, and continuous monitoring through data-driven models. AI-powered tools such as predictive analytics, medical imaging interpretation, and digital health platforms have demonstrated improved clinical decision-making and patient outcomes.

However, the integration of AI into healthcare systems raises critical regulatory challenges, including software validation, data privacy, cybersecurity, algorithm transparency, and classification of AI as Software as a Medical Device (SaMD). In India and globally, regulatory frameworks for AI-enabled medical technologies are still evolving, creating uncertainty in approval, deployment, and post-market surveillance.

Therefore, there is a clear need to systematically review the clinical applications of AI in menorrhagia alongside the regulatory requirements governing such technologies, ensuring their safe, ethical, and effective implementation in healthcare.

**Rationale of the Study**

The rapid advancement of AI in medical diagnostics and treatment has outpaced the development of robust and harmonized regulatory guidelines, particularly in specialized clinical areas such as menstrual health. While AI tools show high potential for improving clinical outcomes, their real-world application depends heavily on regulatory acceptance, compliance, and trustworthiness.

This study is rationalized by the necessity to

Understand how AI technologies are currently being applied in the diagnosis and management of menorrhagia Evaluate regulatory pathways followed by authorities such as CDSCO, FDA, and EMA.

Analyze ethical, legal, and data governance issues associated with AI-based healthcare tool By integrating clinical insights with regulatory perspectives, this study provides a structured understanding of how AI innovations can be responsibly translated from research to routine clinical practice.

**Justification of the Study**

Despite growing research on AI in healthcare, there is limited consolidated literature that jointly addresses clinical effectiveness and regulatory oversight of AI applications in

menorrhagia. Most existing studies focus either on technical performance or clinical outcomes, with insufficient emphasis on regulatory compliance and governance.

This study is justified because it

Bridges the gap between technological innovation and regulatory scienc

Supports evidence-based regulatory decision-making for AI-enabled medical tools

Enhances awareness among researchers, clinicians, and regulatory professionals regarding compliance requirements.

Contributes to safer adoption of AI in women's healthcare

The findings of this study will serve as a valuable academic and regulatory reference, supporting the development, evaluation, and approval of AI-based medical technologies while ensuring patient safety, data protection, and ethical integrity.

## AIM AND OBJECTIVES

### AIM

To study the role of Artificial Intelligence in improving the diagnosis and management of menorrhagia and to review the regulatory requirements for AI-based medical technologies in healthcare.

### OBJECTIVE

1. To understand the clinical significance, diagnosis, and treatment approaches for menorrhagia.
2. To evaluate the applications of Artificial Intelligence in improving clinical decisions and patient outcomes in menorrhagia.
3. To review regulatory pathways and guidelines for AI-based medical devices and software in healthcare by CDSCO (India), FDA (USA), and EMA (Europe).
4. To identify safety, ethical, and data privacy challenges associated with AI in women's healthcare.
5. To propose recommendations for strengthening regulatory compliance and adoption of AI-enabled solutions in gynecology.

**Plan of Work (including timeline)**

| Achievable Targets | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 |
|---|---|---|---|---|---|---|
| Topic selection and approval | ✓ | | | | | |
| Research proposal preparation | ✓ | ✓ | | | | |
| Literature survey on AI and regulatory affairs | ✓ | ✓ | ✓ | | | |
| Review of AI tools and regulatory guidelines (FDA, EMA, CDSCO, ICH) | | ✓ | ✓ | | | |
| Data collection | | | ✓ | ✓ | | |
| Data analysis and interpretation | | | | ✓ | ✓ | |
| Discussion of findings | | | | | ✓ | |
| Preparation of results and conclusion | | | | | ✓ | |
| Thesis writing and compilation | | | | ✓ | ✓ | ✓ |
| Editing, proofreading, and formatting | | | | | ✓ | ✓ |
| Final submission and viva preparation | | | | | | ✓ |

## METHODOLOGY

### 1. Study Design

The present study is designed as a descriptive and analytical review-based study focusing on the application of Artificial Intelligence (AI) for the automation of regulatory dossier preparation, specifically CTD and eCTD submissions. The study systematically evaluates existing scientific literature, regulatory guidelines, and industry practices to assess the role of AI in improving efficiency, accuracy, and regulatory compliance in pharmaceutical submissions.

## 2. Data Source

Data for the study were collected from both national and international sources, including

Peer-reviewed scientific journal

Review articles and regulatory science publications

Books and reference materials related to regulatory affairs and A

Official regulatory authority websites such as Food and Drug Administration (FDA), European Medicines Agency (EMA), Central Drugs Standard Control Organization (CDSCO), International Council for Harmonisation (ICH)

Industry white papers, regulatory reports, and policy documents.

## 3. Literature Search Strategy

A systematic literature search was conducted using relevant keywords such as Artificial Intelligence, Machine Learning, Regulatory Affairs, CTD, eCTD, Regulatory Dossier Automation, and Digital Transformation in Regulatory Submissions. Databases including PubMed, Google Scholar, Scopus, and ScienceDirect were used. Literature published primarily within the last 10–15 years was prioritized to ensure inclusion of recent technological advancements.

## 4. Inclusion Criteria

Studies focusing on AI applications in drug development, regulatory affairs, and dossier preparation

Peer-reviewed articles, review papers, regulatory guidelines, and authoritative report

Publications available in the English languag

Studies providing methodological descriptions and relevant regulatory outcomes.

## 5. Exclusion Criteria

Articles unrelated to pharmaceutical regulatory affairs or AI applications

Studies lacking sufficient methodological or regulatory details

Non-peer-reviewed opinion articles and promotional materials

Abstract-only publications without full-text availability.

## 6. Data Collection and Organization

Relevant information was extracted from selected sources and systematically organized into thematic categories, including:

AI technologies used in regulatory affairs

Automation of CTD/eCTD dossier preparation

AI applications in regulatory submissions and complianc

Benefits of AI in workflow optimization and error reduction

Regulatory, ethical, and legal challenges associated with AI implementation.

## 7. Data Analysis

The collected data were analyzed qualitatively using a comparative and thematic approach. Conventional manual dossier preparation processes were compared with AI-driven approaches to assess improvements in efficiency, accuracy, consistency, and compliance. Key benefits, limitations, and regulatory challenges were identified and interpreted in relation to the study objectives.

## 8. Ethical Considerations

As this study is based entirely on secondary data analysis of publicly available sources, no direct ethical approval was required. Ethical research practices such as proper citation, avoidance of plagiarism, and objective interpretation of findings were strictly followed throughout the study.

## 9. Study Limitations

The methodology is limited by reliance on secondary data and qualitative analysis. Lack of access to proprietary AI tools and real-world implementation data may restrict empirical validation of findings.

## Expected Outcomes

### 1. Comprehensive Evidence Compilation

A detailed summary of current scientific literature on the use of AI in the diagnosis and management of menorrhagia.

### 2. Regulatory Insight

Clear understanding of regulatory pathways, guidelines, and compliance requirements for AI-enabled medical devices in India, USA, and Europe.

### 3. Identification of Gaps & Challenges

Recognition of limitations in current AI applications, regulatory frameworks, and clinical adoption barriers.

**4. Recommendations for Future Practice**

Practical suggestions to enhance regulatory approval processes and safe, effective adoption of AI technologies in gynecology.

**5. Contribution to Academic Knowledge**

Provides a structured review that can serve as a reference for researchers, clinicians, and policymakers interested in AI-based menstrual health solutions.

**6. Evaluation of Ethical and Data Privacy Concerns**

Assessment of ethical considerations, patient data protection issues, and transparency challenges associated with AI-driven healthcare technologies.

**7. Support for Regulatory Decision-Making**

Insights that may assist regulatory authorities and healthcare institutions in developing clearer guidelines for evaluation and monitoring of AI-enabled medical technologies.

**8. Framework for Future Research**

Identification of research gaps and emerging trends to guide future clinical, technological, and regulatory research in AI-driven women's healthcare.

**9. Promotion of Standardization**

Encouragement of harmonized regulatory standards and best practices for AI-based healthcare applications across different global regulatory agencies.

**10. Improved Patient-Centered Outcomes (Indirect)**

Highlighting the potential of AI technologies to improve early diagnosis, treatment continuity, and overall quality of care for patients suffering from menorrhagia.

**ACKNOWLEDGEMENTS**

The author sincerely expresses gratitude to the faculty members and mentors of Dr. Vedprakash Patil Pharmacy College for their valuable guidance, academic support, and encouragement throughout the preparation of this review article. Their insights in the field of Regulatory Affairs and digital health have significantly contributed to the completion of this work.

**Financial Disclosure Statement**

The author declares that no specific funding, grant, or financial support was received from any public, commercial, or non-profit organization for the preparation of this review article.

**Conflict of Interest**

The author declares that there is no conflict of interest regarding the publication of this article. The study was conducted independently and without any commercial or financial influence.

**REFERENCES**

1. Lekadir K, Feragen A, Fofanah AJ, Frangi AF, Buyx A, Emelie A, et al. FUTURE-AI: International consensus guideline for trustworthy and deployable artificial intelligence in healthcare. arXiv, 2023; Available at: https://arxiv.org/.
2. García Gómez JM, Blanes Selva V, de Bartolomé Cenzano JC, Cebolla Cornejo J, Doñate Martínez A. Functional requirements to mitigate the risk of harm to patients from artificial intelligence in healthcare. arXiv, 2023; Available at: https://arxiv.org/.
3. Biasin E, Kamenjasevic E. Cybersecurity of AI medical devices: risks, legislation, and challenges. arXiv, 2023; Available at: https://arxiv.org/.
4. Chen F, Wang L, Hong J, Jiang J, Zhou L. Unmasking Bias in AI: A Systematic Review of Bias Detection and Mitigation Strategies in EHR-based Models. arXiv, 2023; Available at: https://arxiv.org/
5. U.S. Food & Drug Administration. Artificial Intelligence-Enabled Medical Devices. FDA, 2024; Available at: https://www.fda.gov/medical-devices/software-medical-device-.samd/artificial-intelligence-and-machine-learning-software-medical-device.
6. U.S. FDA, CDRH. Predetermined Change Control Plans for Machine Learning-Enabled Medical Devices, 2024; Available at: https://www.fda.gov/.
7. Biasin E, Kamenjašević E. Regulatory approaches towards AI-based medical device cybersecurity: a transatlantic perspective. European Journal of Risk Regulation, 2024; 15: 876–886. Available at: https://www.cambridge.org/.
8. Elbiss HM, et al. Artificial intelligence in gynecologic and obstetric care: a review. Available at: https://www.ncbi.nlm.nih.gov/pmc/.
9. Gbagbo FY, et al. Artificial intelligence and sexual reproductive health: applications and challenges. PMC., 2024; Available at: https://www.ncbi.nlm.nih.gov/pmc/.
10. Kim HK. The Effects of Artificial Intelligence Chatbots on Women's Health: A

Systematic Review and Meta-Analysis. Healthcare, 2024; 12(5): 534. Available at: https://www.mdpi.com/.

11. Addissouky TA, et al. Harnessing technology to revolutionize personalized therapies for metrorrhagia. Scientific Archives, 2024; Available at: https://www.scientificarchives.com/.
12. Luz KP, et al. AI-driven digital innovations for reproductive health. Digital Health, 2025; Available at: https://link.springer.com/.
13. Sales dos Santos GG, et al. Using AI as a technological tool in obstetrics and gynecology. Int J Gynecol Obstet, 2024; Available at: https://obgyn.onlinelibrary.wiley.com/.
14. Habiba M, Benagiano G. The Duration of Menstrual Blood Loss: Historical to Current Understanding. Reproductive Medicine, 2023; 4(3): 145–165. Available at: https://www.mdpi.com/.
15. Khan A. AI-driven treatment pathways for heavy menstrual bleeding based on biomarkers. Pak J Med Clin Res., 2025.
16. Sivajohan B, Elgendi M, Menon C, Allaire C, Yong P, Bedaiwy M. Clinical use of AI in endometriosis: a scoping review. npj Digital Medicine, 2022; Available at: https://www.nature.com/npjdigitalmed/.
17. Sneha Mavis M, et al. Endometriosis and Artificial Intelligence: Advancing Women's Health. IJPPR, 2024.
18. Zhang S, Li Y, Liu W, Chu Q, Wang S, Li J, et al. A decade of review in global regulation and research of AI medical devices (2015–2025). Frontiers in Medicine, 2025; Available at: https://www.frontiersin.org/.
19. UK Government / MHRA. Regulation of Artificial Intelligence as a Medical Device (AIaMD). GOV.UK, 2023–2024. Available at: https://www.gov.uk/.
20. World Health Organization. Ethics and governance of artificial intelligence for health. WHO, 2023–2024; Available at: https://www.who.int/.
21. Warraich HJ, Tazbaz T, Califf RM. FDA Perspective on the Regulation of AI in Health Care and Biomedicine. JAMA, 2024; Available at: https://jamanetwork.com/.
22. Nasarian E, Alizadehsani R, Acharya UR, Tsui KL. Designing interpretable ML systems to enhance trust in healthcare. arXiv, 2023; Available at: https://arxiv.org/.
23. Wei Q, et al. Ultrasound AI in diagnosis of uterine diseases. Digital Health, 2025; Available at: https://journals.sagepub.com/.
24. Zakall J, Pohn B, Graf A, et al. AI and medical imaging in IVF ovarian stimulation. arXiv, 2024; Available at: https://arxiv.org/.

25. Shopova A, Lippert C, Shaw LJ, Alleva E. Multi-Task Learning for Extracting Menstrual Characteristics from Clinical Notes. arXiv, 2025; Available at: https://arxiv.org/.
26. Wei Q, et al. AI-based automation in regulatory submissions: Enhancing CTD/eCTD workflows. Drug Discovery Today, 2025; 30(3): 410–418. Available at: https://www.sciencedirect.com/journal/drug-discovery-today.
27. Luz KP, et al. Digital transformation of regulatory affairs through AI. Journal of Digital Medicine, 2025; 8: 101–115. Available at: https://link.springer.com/.
28. Zhang Y, et al. AI-enabled document management systems for pharmaceutical regulatory submissions. Regulatory Science Advances, 2025; 6(1): 22–35. Available at: https://link.springer.com/.
29. Kim HK. AI applications in regulatory documentation and compliance. Digital Health. 2024; 10: 20552076241234567. Available at: https://journals.sagepub.com/home/dhj.
30. Zhou K, Gattinger G. Regulatory evolution and AI integration in CTD/eCTD submissions. Therapeutic Innovation & Regulatory Science, 2024; 58(4): 520–529. Available at: https://journals.sagepub.com/home/tir.
31. Santra S, et al. Artificial intelligence for regulatory document lifecycle management. Frontiers in Public Health, 2024; 12: 1120. Available at: https://www.frontiersin.org/journals/public-health.
32. Springer T, et al. AI, data integrity, and regulatory compliance in pharmaceutical submissions. European Journal of Health Law, 2024; 31(2): 110–125. Available at: https://brill.com/view/journals/ejhl/ejhl-overview.xml
33. Warraich HJ, et al. FDA regulatory perspective on AI-driven automation tools. Regulatory Affairs Journal, 2024; 10(2): 45–53. Available at: https://www.topra.org/.
34. Addissouky TA, et al. AI-driven compliance verification in regulatory submissions. Journal of Regulatory Science, 2024; 12(1): 65–78. Available at: https://www.journalofregulatoryscience.com.
35. Sovrano F, Lognoul M, Vilone G. Explainable AI and regulatory compliance for medical software. arXiv, 2024; Available at: https://arxiv.org/.